The key considerations when selecting whether to start adjuvant or neoadjuvant chemotherapy for patients with IBC-NSTs are tumour size, nodal status, nuclear grade, age, tumour subtype determined by IHC for ER, PgR, and HER2, and the Ki67 index. Here, ERBB2 is linked to inflammatory breast carcinoma.